eli lilly glp-1 drugs Lilly's oral pill may help people with Type 2 diabetes lose 'significant' weight, study finds The FDA has approved a
Description
G., Ross, F
Pharmacotherapy 37 , 927943 (2017)

Undoubtably, dysregulation of these peptide systems contributes to overweight, disproportion in body composition, obesity and eating disorders

The negative attitude of Novo Nordisk was summed up by Lars Srenson, the company's CEO, who in 2005 argued 'Obesity is primarily a social and cultural problem

PMC 5114298